Partner and Licensing Opportunities
New York Blood Center Enterprises (NYBCe)—one of the United States' leading suppliers of blood products and services—boasts world-class research that has paved the way for new blood-related products, techniques and therapies resulting in numerous landmark patents and licenses.
Heparin-Induced Thrombocytopenia and Thrombosis (HITT)
Under the leadership of Vice President and Chief Medical Officer, Bruce Sachais, MD, PhD, the Platelet Research Laboratory's focus is on improved diagnosis and novel therapeutics for heparin-induced thrombocytopenia/thrombosis (HITT). Platelet factor 4 antagonists (PF4As) represent a novel approach to the treatment and prevention of HITT, and show tremendous potential for this disorder.
Current drugs (general antithrombotics) used for treating HIT/HITT are generally not very effective and have safety issues regarding bleeding. Lead candidate-FC-7259 directly addresses the pathophysiology of HITT with little or no increased risk of bleeding and has good drug properties for IV administration.
NYBC is seeking partnership(s) to take this lead PF4A ( FC-7259) to IND. Learn more about our Small Molecule Antagoists of PF4 for the Treatment and Prevention of HITT by clicking the button below.
Connect with Us
Our experienced team, led by Executive Vice President and Chief Financial and Business Officer, Jay Mohr, has deep expertise in basic research, business development, M&A and complex operations and integration.